Will Europe Miss The Boat On ATMPs?
Europe lags in ATMP adoption due to low profitability, R&D spending, and clinical challenges, requiring innovative pricing and reimbursement for early access.
Europe lags in ATMP adoption due to low profitability, R&D spending, and clinical challenges, requiring innovative pricing and reimbursement for early access.
What are ATMPs, and why the buzz? Inbeeo hosted a webinar addressing their market impact, focusing on US and EU challenges with 60+ participants in the Q&A.
Was the reaction to the $2.15m Zolgensma list price a tropical cyclone or more of a storm in a teacup?